Pacala Mark L's Form 4 filing
Starling Oncology, Inc. (DFPH) · filed Nov 20, 2025
- Accession no.
- 0001079973-25-001813
- Filed
- Nov 20, 2025
- Trade date
- Nov 18, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market sales total $200.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Pacala Mark LCIK 0001321250 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 18, 2025 | Common Stock | SSaleDisposed | −2,160 | $4.00 | −$8,640 | 222,811 | Direct | |
| Nov 18, 2025 | Common Stock | SSaleDisposed | −1,210 | $4.00 | −$4,840 | 221,601 | Direct | |
| Nov 18, 2025 | Common Stock | SSaleDisposed | −46,630 | $4.00 | −$186,520 | 174,971 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.